HRs for discontinuing treatment with (A) biosimilar versus originator (reference) infliximab, (B) biosimilar versus originator (reference) etanercept
| A. CT-P13 versus INF HR (95% CI) | B. SB4 versus ETN HR (95% CI) | |
| Crude | 0.95 (0.79 to 1.15) | 0.82 (0.63 to 1.07) |
| Adjusted* | ||
| Sex, age, csDMARD | 0.94 (0.78 to 1.14) | 0.84 (0.64 to 1.09) |
| Sex, age, csDMARD, CRP | 0.94 (0.78 to 1.14) | 0.84 (0.65 to 1.09) |
| Sex, age, csDMARD, patient global | 0.93 (0.77 to 1.13) | 0.84 (0.65 to 1.09) |
*Adjusted for baseline characteristics, all patients are included in the multivariable analyses due to the categorisation of the variables (see Patients and methods section).
CRP, C reactive protein;csDMARD, conventional synthetic disease-modifying antirheumatic drug; CT-P13, infliximab biosimilar; ETN, etanercept originator; INF, infliximab originator; SB4, etanercept biosimilar.